Acetylcholinesterase inhibitors and drugs acting on muscarinic receptors-potential crosstalk of cholinergic mechanisms during pharmacological treatment

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F60162694%3AG44__%2F17%3A43875754" target="_blank" >RIV/60162694:G44__/17:43875754 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11160/17:10361342 RIV/00179906:_____/17:10361342

Výsledek na webu

<a href="http://www.eurekaselect.com/143096/article" target="_blank" >http://www.eurekaselect.com/143096/article</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.2174/1570159X14666160607212615" target="_blank" >10.2174/1570159X14666160607212615</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Acetylcholinesterase inhibitors and drugs acting on muscarinic receptors-potential crosstalk of cholinergic mechanisms during pharmacological treatment

Popis výsledku v původním jazyce

Most pharmaceuticals targeting muscarinic receptors are employed at such large doses that no selectivity can be expected. However, some differences in the adverse effect profile of muscarinic antagonists may still be explained by the variation of expression of muscarinic receptor subtypes in different organs. However, a complex pattern of interactions between muscarinic receptor subtypes occurs and needs to be considered when searching for selective pharmaceuticals. In the development of new entities for the treatment of for instance pesticide intoxication, the muscarinic receptor selectivity needs to be considered. Reactivators generally have a muscarinic M2 receptor acting profile. Such a blockade may engrave the situation since it may enlarge the effect of the muscarinic M3 receptor effect. This may explain why respiratory arrest is the major cause for deaths by esterase blocking.

Název v anglickém jazyce

Acetylcholinesterase inhibitors and drugs acting on muscarinic receptors-potential crosstalk of cholinergic mechanisms during pharmacological treatment

Popis výsledku anglicky

Most pharmaceuticals targeting muscarinic receptors are employed at such large doses that no selectivity can be expected. However, some differences in the adverse effect profile of muscarinic antagonists may still be explained by the variation of expression of muscarinic receptor subtypes in different organs. However, a complex pattern of interactions between muscarinic receptor subtypes occurs and needs to be considered when searching for selective pharmaceuticals. In the development of new entities for the treatment of for instance pesticide intoxication, the muscarinic receptor selectivity needs to be considered. Reactivators generally have a muscarinic M2 receptor acting profile. Such a blockade may engrave the situation since it may enlarge the effect of the muscarinic M3 receptor effect. This may explain why respiratory arrest is the major cause for deaths by esterase blocking.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30104 - Pharmacology and pharmacy

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2017

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Current Neuropharmacology

ISSN

1570-159X

e-ISSN

—

Svazek periodika

15

Číslo periodika v rámci svazku

4

Stát vydavatele periodika

AE - Spojené arabské emiráty

Počet stran výsledku

17

Strana od-do

637-653

Kód UT WoS článku

000402461000012

EID výsledku v databázi Scopus

2-s2.0-85010685416